Compare Adaptive Biotechnologies Corp (ADPT) vs KE Holdings Inc (BEKE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs KE Holdings Inc — how do they compare? Adaptive Biotechnologies Corp trades at $19.96 (market cap $3.33B), while KE Holdings Inc trades at $15.34 (market cap $16.40B). The key difference: KE Holdings Inc is far larger — about 4.9× Adaptive Biotechnologies Corp's market cap, and KE Holdings Inc pays a 1.86% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | BEKE | |
|---|---|---|
Market Cap | $3.33B | $16.40B |
Sector | Health | Technology |
52-Week High | $22.37 | $20.36 |
52-Week Low | $10.24 | $14.26 |
Enterprise Value | $3.19B | $12.17B |
Dividend Yield | — | 1.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
BEKE trades at $15.02, down 0.46% with a bearish technical signal. The company reported strong Q1 2026 earnings beating expectations with EPS of $0.20 versus $0.14 expected, driven by improved profitability despite lower revenue. Analyst sentiment remains overwhelmingly positive with 91.7% buy ratings. Recent news highlights potential trend reversal opportunities after a 14.1% decline over four weeks.
The outlook suggests potential upside with improving operational efficiency and cost controls offsetting market softness. Key risks include China's property market volatility and competitive pressures. With strong institutional support and positive earnings momentum, BEKE presents a compelling growth story despite near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About KE Holdings Inc
KE Holdings (Beike) is China’s leading platform for housing transactions and services. It operates the Lianjia brand and uses data-driven technology to facilitate home sales, rentals, and home renovation services.
Read more on BEKE →
